XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2021
USD ($)
Sep. 30, 2021
customer
Sep. 30, 2020
customer
Dec. 31, 2020
customer
Asset Purchase Agreement with ConSynance Therapeutics [Member] | HBS-102 | All Countries Excluding Greater China        
Summary Of Significant Accounting Policies [Line Items]        
Consideration transferred $ 3,500      
Payment for intellectual property upon preclinical milestones 1,750      
Payment for intellectual property upon developmental milestones 19,000      
Payment for intellectual property upon regulatory milestones 44,000      
Payment for intellectual property upon sales milestones $ 110,000      
Accounts Receivable        
Summary Of Significant Accounting Policies [Line Items]        
Number of customers | customer   3   3
Product Revenues        
Summary Of Significant Accounting Policies [Line Items]        
Number of customers | customer   3 3  
Three Customers | Accounts Receivable | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   100.00%   100.00%
Three Customers | Product Revenues | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   100.00% 100.00%  
Caremark LLC | Accounts Receivable | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   36.00%   44.00%
Caremark LLC | Product Revenues | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   36.00% 40.00%  
PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   34.00%   23.00%
PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   36.00% 34.00%  
Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   30.00%   33.00%
Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage   28.00% 26.00%